2023-11-28 07:00:09
Published on Nov. 28, 2023 at 8:00 a.m.
This is good news for the Nantes biotech, which had experienced numerous setbacks with its vaccine once morest Covid-19. On November 10, it received the green light from the FDA (the American health authority) for the marketing of VLA1553. Called Ixchiq, its commercial name, it is the world’s first vaccine once morest chikungunya.
This virus transmitted by tiger mosquitoes occurs particularly in Africa, Asia and the Indian subcontinent. In recent decades, chikungunya-carrying mosquitoes have reached Europe and the Americas. As of July 2022, more than three million cases have been recorded on the American continent alone. Can cause high fevers and intense joint pain, the disease can also leave following-effects. The results of a phase III study, published this month, showed, following six months, protective antibody levels in 96.3% of the 4,000 adults tested, as well as a good safety profile.
1701167990
#worlds #vaccine #chikungunya #French #developed #Nantes #biotech #Valneva
